Tag Archives: impaired glucose tolerance
March 2014 Br J Cardiol 2014;21:16
In brief
BJCardio Staff
New drugs for diabetes A new DPP-4i for the management of type 2 diabetes, alogliptin (Vipidia®) has been launched by Takeda in the UK following data from EXAMINE, an outcome trial conducted in high risk acute coronary syndrome patients (see Br J Cardiol 2013;4:131) where the drug significantly reduced glucose levels and also demonstrated cardiovascular safety. Alogliptin and the fixed-dose combination product alogliptin and metformin (Vipdomet®) are now available in the UK. Alogliptin is licensed for the treatment of type 2 diabetes mellitus in adults aged 18 years and older to improve glycaemic control in combination with other glucose-lo
April 2011 Br J Cardiol 2011;18:78−81
Drugs for diabetes: part 4 acarbose
Ganesan Arungarinathan, Gerard A McKay, Miles Fisher
(more…)
March 2004 Br J Cardiol 2004;11:138-43
Will prevention of type 2 diabetes reduce the future burden of cardiovascular disease? The evidence base today
ohn HB Scarpello
No content available
For healthcare professionals only
